by rvvadmin | Mar 20, 2020 | 2020
TORONTO, March 20, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company, is pleased to announce that it is exploring the use of the drug Bucillamine as a potential novel treatment for infectious diseases including...
by rvvadmin | Mar 18, 2020 | 2020
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, March 18, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a cannabis and...
by rvvadmin | Mar 5, 2020 | 2020
TORONTO, March 05, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”), a company focused on the research, development and commercialization of novel psychedelic and cannabinoid-based life sciences products, is pleased to announce that, further to its...
by rvvadmin | Feb 18, 2020 | 2020
TORONTO, Feb. 18, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”), a company focused on the research, development and commercialization of novel cannabinoid-based and life sciences products, is pleased to provide an update on the Company’s clinical...
by rvvadmin | Feb 12, 2020 | 2020
TORONTO, Feb. 12, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) is pleased to announce that it has entered into a letter of intent, dated February 11, 2020 (the “LOI”) with Psilocin Pharma Corp. (“Psilocin”), an arm’s length party incorporated...
by rvvadmin | Feb 11, 2020 | 2020
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Feb. 11, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”), a cannabis life sciences...
